Press Release For Immediate Release

Glenmark Generics receives Final Approval from USFDA for Mupirocin ointment

June 10, 2011: Glenmark Generics Inc., USA the subsidiary of Glenmark Generics Limited, has been granted final abbreviated new drug approval (ANDA) from the United States Food and Drug Administration (U.S. FDA) for Mupirocin ointment USP, 2%.

Mupirocin ointment is indicated for the topical treatment of impetigo due to: Staphylococcus aureus and Streptococcus pyogenes and is available in a 22 gram tube presentation. Based on IMS Health sales data for the 12 month period ending March 2011, mupirocin ointment garnered annual sales of USD 55 million and achieved a 9% increase in growth compared to the same period last year.

Glenmark's current portfolio consists of 68 products authorized for distribution in the U.S. marketplace and 39 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.

About Glenmark Generics limited.
Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America, a developing EU presence and Argentina and maintains marketing front-ends in these countries. It primarily sells its FDF products in the United States ("US") and the European Union ("EU"), as well as its oncology FDF products in South America. The Company supplies APIs to customers in approximately 63 countries, including the US, various countries in the EU, South America and India.

#####

For further information, please contact:
Jason D'Souza
Glenmark, Mumbai, India Tel: [+91 22] 40189919
Email : connect@glenmark-generics.com